Renalytix AI PLC Presentation of KidneyIntelX Health Economics Data
March 27 2020 - 2:00AM
RNS Non-Regulatory
TIDMRENX
Renalytix AI PLC
27 March 2020
Renalytix AI plc
("RenalytixAI", the "Company")
Presentation of KidneyIntelX(TM) Health Economics Data
Renalytix AI plc (LSE : RENX), the AIM-traded developer of
clinical grade artificial intelligence in vitro diagnostics for
kidney disease, announces that further to RNS Reach 2937H on 24
March 2020, Boston Healthcare Associates has presented data on
KidneyIntelX(TM) , the Company's AI-enabled in vitro diagnostic
test for kidney disease, and the clinical and health economic
benefit from deploying the test in large health systems in the
United States during National Kidney Foundation's Spring Clinical
Meeting.
A poster summarizing the data presented by Boston Healthcare is
now available through the conference website and at
https://renalytixai.com/investors/utility-and-impact-of-kidneyintelx
.
It is estimated that there are 12 million individuals with
diabetic kidney disease (DKD) in the United States alone. The
economic impact model estimates that KidneyIntelX(TM) testing of
100,000 individuals with DKD, with the assumption of a 20% relative
decrease in DKD progression for the 16% of DKD individuals scored
as "high-risk" by KidneyIntelX(TM) patients, could deliver
cumulative savings of more $1 billion over a five-year period. The
presentation was delivered by Thomas Goss, PharmD, Senior Vice
President, Boston Healthcare Associates.
During the presentation, Dr. Goss described the population
health benefits that can be realized with system-wide adoption of
KidneyIntelX(TM) . These include delaying progression to more
advanced stages of DKD, reducing hospitalizations, and avoiding
unplanned emergency room crashes onto dialysis, and delaying or
preventing end stage kidney disease, and related dialysis and
kidney transplant procedures. These outcomes will not only lead to
a significant improvement in quality of life for diabetic kidney
disease patients, they also can drive significant cost benefit for
health providers and insurers. The model developed by Boston
Healthcare demonstrates that a health insurer will realize net
savings in less than two years, assuming a one-time use of the
test. Based on 100,000 patients tested, annual savings increase
each year and peak at $685 million in year five. This combination
of significantly improved patient outcomes, optimal utilization of
healthcare resources, and savings for health insurers is expected
to lead to an increase in coverage determinations for
KidneyIntelX(TM) from private insurers in the United States in both
2020 and 2021.
NKF's Spring Clinical Meeting gathers more than 3,000 nephrology
healthcare professionals from across the United States to learn
about the newest developments related to all aspects of nephrology
practice. Due to the coronavirus and coronavirus disease (COVID-19)
outbreak in the United States the meeting is being held as a live
virtual event in 2020. Sessions can be accessed through the
conference website. For information about the NKF's virtual
conference event, visit https://www.kidney.org/spring-clinical
.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of clinical grade, artificial
intelligence-enabled in vitro diagnostic solutions for kidney
disease, one of the most common and costly chronic medical
conditions globally. The Company's products are being designed to
make significant improvements in kidney disease diagnosis,
transplant management, clinical care, and patient stratification
for drug clinical trials. For more information, visit
renalytixai.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADXGDXBBDDGGL
(END) Dow Jones Newswires
March 27, 2020 03:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024